Literature DB >> 34049316

DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base: Detailed Clinicopathologic Characterization of a Distinctive Entity.

Lisa M Rooper1, Abbas Agaimy, Brendan C Dickson, Julie C Dueber, Charles G Eberhart, Jeffrey Gagan, Arndt Hartmann, Armen Khararjian, Nyall R London, Christina M MacMillan, Doreen N Palsgrove, J Stephen Nix, Ann Sandison, Robert Stoehr, Tra Truong, Ilan Weinreb, Justin A Bishop.   

Abstract

A novel DEK-AFF2 fusion was recently reported in 4 nonkeratinizing squamous cell carcinomas of the sinonasal region and skull base, including 1 with exceptional response to immunotherapy, but it is not yet clear if this rearrangement defines a unique clinicopathologic category or represents a rare event. This study aims to characterize a larger cohort of carcinomas with DEK-AFF2 fusions to assess whether they truly constitute a distinctive entity. Among 27 sinonasal and skull base nonkeratinizing squamous cell carcinoma that were negative for human papillomavirus and Epstein-Barr virus, RNA sequencing identified DEK-AFF2 fusions in 13 cases (48%). Nine were centered in the nasal cavity, 2 in the middle ear/temporal bone, 1 in the nasopharynx, and 1 in the orbit. These tumors displayed recurrent histologic features including (1) complex endophytic and exophytic, frequently papilloma-like growth, (2) transitional epithelium with eosinophilic to amphophilic cytoplasm, (3) absent or minimal keratinization with occasional compact keratin pearls, (4) monotonous nuclei, and (5) prominent tumor-infiltrating neutrophils or stromal lymphocytes. This appearance not only overlaps with high-grade basaloid sinonasal carcinomas but also with benign papillomas and tumors reported as low-grade papillary Schneiderian carcinoma. However, DEK-AFF2 carcinomas showed frequent local recurrence, cervical lymph node metastases, and distant metastasis with 2 deaths from disease, confirming they are aggressive malignancies despite relatively bland histology. Overall, the distinctive molecular, histologic, and clinical features of DEK-AFF2 carcinomas suggest they represent a unique entity in the sinonasal region. This tumor merits increased pathologic recognition to better understand its prognostic and therapeutic implications.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34049316     DOI: 10.1097/PAS.0000000000001741

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

Review 1.  Development of head and neck pathology in Europe.

Authors:  Henrik Hellquist; Abbas Agaimy; Göran Stenman; Alessandro Franchi; Alfons Nadal; Alena Skalova; Ilmo Leivo; Nina Zidar; Roderick H W Simpson; Pieter J Slootweg; Juan C Hernandez-Prera; Alfio Ferlito
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

2.  First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.

Authors:  Omid Savari; Jason C Chang; Justin A Bishop; Muthu Kumar Sakthivel; Frederic B Askin; Natasha Rekhtman
Journal:  J Thorac Oncol       Date:  2022-06-28       Impact factor: 20.121

3.  A novel WWTR1::AFF2 fusion in an intra-abdominal soft tissue sarcoma with associated endometriosis.

Authors:  Nooshin K Dashti; Josephine K Dermawan; J Kenneth Schoolmeester; Kevin C Halling; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2022-04-26       Impact factor: 4.263

Review 4.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Nasal Cavity, Paranasal Sinuses and Skull Base.

Authors:  Lester D R Thompson; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2022-03-21

5.  Temporal Bone Squamous Cell Carcinoma: Molecular Markers Involved in Carcinogenesis, Behavior, and Prognosis: A Systematic Review.

Authors:  Lara Alessandrini; Laura Astolfi; Leonardo Franz; Erica Gentilin; Antonio Mazzoni; Elisabetta Zanoletti; Gino Marioni
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

6.  SCHOOL: Software for Clinical Health in Oncology for Omics Laboratories.

Authors:  Chelsea K Raulerson; Erika C Villa; Jeremy A Mathews; Benjamin Wakeland; Yan Xu; Jeffrey Gagan; Brandi L Cantarel
Journal:  J Pathol Inform       Date:  2022-01-05

Review 7.  Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment.

Authors:  Mario Turri-Zanoni; Giacomo Gravante; Paolo Castelnuovo
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

Review 8.  Towards a Molecular Classification of Sinonasal Carcinomas: Clinical Implications and Opportunities.

Authors:  Cecilia Taverna; Abbas Agaimy; Alessandro Franchi
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639

9.  A novel LARGE1-AFF2 fusion expanding the molecular alterations associated with the methylation class of neuroepithelial tumors with PATZ1 fusions.

Authors:  Guillaume Chotard; François le Loarer; Jessica Baud; Rihab Azmani; Arnault Tauziède-Espariat; Volodia Dangouloff-Ros; Nathalie Boddaert; Céline Icher-de-Bouyn; Edouard Gimbert; Lauren Hasty; Alice Métais; Fabrice Chrétien; Pascale Varlet
Journal:  Acta Neuropathol Commun       Date:  2022-02-03       Impact factor: 7.801

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.